Astex Pharmaceuticals is a world leader in innovative drug discovery and development. The company has successfully applied its proprietary Fragment-Based Drug Discovery (FBDD) platform to generate multiple new drug candidates that are progressing in clinical development. Successful collaborations have led to two launched oncology drugs (Kisqali® partnered with Novartis and BalversaTM partnered with Janssen). Astex continues to grow and focuses on Oncology and Neurological Disorders.
Historically Astex’s fragment screening platform has relied upon X-ray crystallography to support structure-based drug discovery (SBDD) and Astex has comprehensive in-house X-ray crystallography facilities. However, the increased ability of cryo-EM to deliver atomic resolution structures has led to Astex establishing a state of the art, in-house, cryo-EM facility. This facility includes two Glacios and one Krios transmission electron microscopes (TEMs), a fully equipped cryo-EM sample preparation laboratory and extensive computing infrastructure. Astex has also developed custom data collection and processing workflows to facilitate the rapid generation and interpretation of cryo-EM structures for SBDD and FBDD.
Astex’s Molecular Sciences group currently has multiple, fixed term contract, opportunities available for scientists working in cryo-EM. We are seeking highly driven scientists who are keen to help develop Astex’s cryo-EM capabilities and Astex’s general FBDD/SBDD platform. The positions are all based in Cambridge, UK.
For more information:
